Literature DB >> 15046662

KRIT1/cerebral cavernous malformation 1 protein localizes to vascular endothelium, astrocytes, and pyramidal cells of the adult human cerebral cortex.

Ozlem Guzeloglu-Kayisli1, Nduka M Amankulor, Jennifer Voorhees, Guven Luleci, Richard P Lifton, Murat Gunel.   

Abstract

OBJECTIVE: Mutations in KRIT1 cause familial cerebral cavernous malformation, an autosomal dominant disorder affecting primarily the central nervous system vasculature. Although recent studies have suggested that Krev-1 interaction trapped 1 (KRIT1) is a microtubule-associated protein that interacts with integrin cytoplasmic domain-associated protein-1alpha, the function of KRIT1 remains elusive.
METHODS: We used Western blotting and immunohistochemistry with specific KRIT1 polyclonal antibodies to investigate KRIT1 protein expression in diverse cerebral and extracerebral tissues.
RESULTS: Immunostaining demonstrates that although KRIT1 is expressed in a broad variety of human organs, it localizes to the vascular endothelium of each, specifically to capillaries and arterioles. KRIT1 antibody fails to stain fenestrated capillaries in the kidney, the liver, or the red pulp of the spleen, where endothelial cells do not to adhere to one another. In contrast, intense staining is observed in the thymus and the white pulp of the spleen, where specialized blood-organ barriers are formed. Other cell types, including various epithelia, cardiac myocytes, and hepatocytes, also stain with KRIT1.
CONCLUSION: Although KRIT1 expression is seen in every endothelium studied, cerebral cavernous malformation lesions are seen almost exclusively in the central nervous system, suggesting that additional cell type(s) contribute to the pathophysiology of cerebral cavernous malformations. Here, we demonstrate that KRIT1 is also present in cells and structures integral to the cerebral angiogenesis and formation of the blood-brain barrier, namely, endothelial cells and astrocytic foot processes, as well as pyramidal neurons in the cerebral cortex.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15046662     DOI: 10.1227/01.neu.0000114512.59624.a5

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  23 in total

1.  Symptomatic spinal cavernous malformations: indication for microsurgical treatment and outcome.

Authors:  Homajoun Maslehaty; Harald Barth; Athanassios K Petridis; Alexandros Doukas; Hubertus Maximilian Mehdorn
Journal:  Eur Spine J       Date:  2011-07-14       Impact factor: 3.134

Review 2.  Genetics of cerebral cavernous malformations.

Authors:  Nicholas W Plummer; Jon S Zawistowski; Douglas A Marchuk
Journal:  Curr Neurol Neurosci Rep       Date:  2005-09       Impact factor: 5.081

Review 3.  Cerebral cavernous malformation: new molecular and clinical insights.

Authors:  N Revencu; M Vikkula
Journal:  J Med Genet       Date:  2006-03-29       Impact factor: 6.318

4.  Cerebral cavernous malformation protein CCM1 inhibits sprouting angiogenesis by activating DELTA-NOTCH signaling.

Authors:  Joycelyn Wüstehube; Arne Bartol; Sven S Liebler; René Brütsch; Yuan Zhu; Ute Felbor; Ulrich Sure; Hellmut G Augustin; Andreas Fischer
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-24       Impact factor: 11.205

Review 5.  Cerebral cavernous malformations: from molecular pathogenesis to genetic counselling and clinical management.

Authors:  Remco A Haasdijk; Caroline Cheng; Anneke J Maat-Kievit; Henricus J Duckers
Journal:  Eur J Hum Genet       Date:  2011-08-10       Impact factor: 4.246

6.  Stabilization of VEGFR2 signaling by cerebral cavernous malformation 3 is critical for vascular development.

Authors:  Yun He; Haifeng Zhang; Luyang Yu; Murat Gunel; Titus J Boggon; Hong Chen; Wang Min
Journal:  Sci Signal       Date:  2010-04-06       Impact factor: 8.192

Review 7.  Cerebral cavernous malformation proteins at a glance.

Authors:  Kyle M Draheim; Oriana S Fisher; Titus J Boggon; David A Calderwood
Journal:  J Cell Sci       Date:  2014-01-30       Impact factor: 5.285

Review 8.  Control of cell adhesion dynamics by Rap1 signaling.

Authors:  Benjamin Boettner; Linda Van Aelst
Journal:  Curr Opin Cell Biol       Date:  2009-07-16       Impact factor: 8.382

9.  Biallelic somatic and germline mutations in cerebral cavernous malformations (CCMs): evidence for a two-hit mechanism of CCM pathogenesis.

Authors:  Amy L Akers; Eric Johnson; Gary K Steinberg; Joseph M Zabramski; Douglas A Marchuk
Journal:  Hum Mol Genet       Date:  2008-12-16       Impact factor: 6.150

Review 10.  Distinct functions for Rap1 signaling in vascular morphogenesis and dysfunction.

Authors:  Magdalena Chrzanowska-Wodnicka
Journal:  Exp Cell Res       Date:  2013-08-02       Impact factor: 3.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.